Intensive Glycemic Control Lowers Plasma Visfatin Levels in Patients with Type 2 Diabetes

Abstract

Visfatin is an independent association factor for type 2 diabetes mellitus (T2DM). In order to evaluate the plasma visfatin levels and investigate whether plasma visfatin concentrations are altered by intensive glycemic control in patients with diabetes, we determined plasma visfatin concentrations and metabolic parameters in 53 newly diagnosed type 2 diabetic patients and 35 healthy controls. Visfatin levels were also investigated before and after intensive glycemic control for three months in subgroup of patients with T2DM. Plasma visfatin levels were significantly elevated in diabetic patients compared with healthy controls (p<0.001). Circulating visfatin concentration was associated with fasting plasma glucose (FPG), 2-hour OGTT plasma glucose (2hPG), HOMA-β indexes (r=0.338, p=0.001; r=0.340, p=0.002; r=−0.296, p=0.006, respectively), but not with insulin sensitivity (HOMA-IR) or other metabolic or anthropometric parameters in all subjects. In addition, visfatin levels were also correlated with HbA1c levels in diabetic patients. Furthermore, visfatin concentrations reduced from 25.0±6.5 ng/ml at baseline to 20.3±4.7 ng/ml (p<0.01) after 3 months of intensive glycemic control, while HbA1c levels decreased from 9.0±1.8% to 6.2±0.7% (p<0.01). We conclude that the change of visfatin concentration may be a compensatory mechanism to ameliorate insulin deficiency due to pancreatic β-cell dysfunction.

Key words

visfatin - type 2 diabetes mellitus - intensive glycemic control

References

• 1 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.  Science. 2005;  307 426-430
• 2 Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue-an update.  Horm Metab Res. 2007;  39 314-321
• 3 Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat epotspecific mRNA expression in humans.  Diabetes. 2005;  54 2911-2916
• 4 Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2006;  91 295-299
• 5 Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U. Visfatin is an adipokine, but it is not regulated by thiazolidinediones.  J Clin Endocrinol Metab. 2006;  91 1181-1184
• 6 Arner P. Visfatin: a true or false trail to type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2006;  91 28-30
• 7 Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from the PIOSTAT study.  Horm Metab Res. 2007;  39 764-768
• 8 Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin.  Diabetologia. 2006;  49 1909-1914
• 9 López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive beta-cell deterioration.  Diabetes. 2006;  55 2871-2875
• 10 Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.  Exp Clin Endocrinol Diabetes. 2006;  114 544-548
• 11 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
• 12 Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, Han JF, Zhao Y, Li G, Luo M. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.  Diabet Med. 2006;  23 967-973
• 13 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study.  Diabetes Care. 2007;  30 318-324
• 14 Mills GW, Avery PJ, MacCarthy MI, Hattersley AT, Levy JC, Hitman GA, Sampson M, Walker M. Heritability estimates for β cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes.  Diabetologia. 2004;  47 732-738
• 15 Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.  J Clin Endocrinol Metab. 2006;  91 1578-1581
• 16 Böttcher Y, Teupser D, Enigk B, Berndt J, Klöting N, Schön MR, Thiery J, Blüher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat depot specific mRNA expression in humans.  J Clin Endocrinol Metab. 2006;  91 2725-2731
• 17 Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, Papasteriades C, Raptis SA. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women.  Horm Metab Res. 2007;  39 758-763
• 18 Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor.  FEBS Lett. 2003;  544 74-78
• 19 Samal B, Sun Y, Stearns G, Xie C, Suggs S, MacNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor.  Mol Cell Biol. 1994;  14 1431-1437
• 20 Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.  J Clin Invest. 2004;  113 1318-1327
• 21 Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.  Microvasc Res. 2005;  70 142-151
• 22 Veer E van der, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD⁺-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation.  Circ Res. 2005;  97 25-34
• 23 Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis.  Eur J Immunol. 2002;  32 3225-3234
• 24 Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.  Diabetes Res Clin Pract. 2007;  75 327-332
• 25 Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.  Diabetes Care. 2004;  27 2597-2602
• 26 Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.  J Endocrinol. 2005;  185 R1-R8
• 27 Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.  Am J Physiol Endocrinol Metab. 2005;  289 E586-E590
• 28 Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P. TNF-alpha alters visfatin and adiponectin levels in human fat.  Horm Metab Res. 2007;  39 250-255

Authors state that they have no confl ict of interest.

Correspondence